Канакинумаб (ингибитор интерлейкина 1β) — прорыв в возможностях противовоспалительной терапии при подагре

1. <div><p>Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007—2008. Arthr Rheum 2011;63:3136-41.</p><p>Edvards N.L. Treatment-failure gout gout: a moving target (editional). Arthr Rheum 2008;58:2587-90.</p><p>Brook R.A., Forsythe A., Smeeding J.E. at al. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Med 2010;26:2813-21.</p><p>Dodghramji P.P., Edvards N.L., McTigue J. Managing gout in the primary care setting: what you and your patients need to know. Am J Med 2010;123:S2.</p><p>Pascual E., Sivera F. Why is gout so poorly managed? [editorial]. Ann Rheum Dis 2007;66:1269-70.</p><p>Singh J.A., Hodges J.S., Toscano J.P., Asch S.M. Quality of care for gout in the US needs improvement. Arthr Rheum 2007;57:822-9.</p><p>Primatesta P., Plana E., Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 2011;12:103.</p><p>Becker M.A., Schumacher H.R. Jr, Wortmann R.L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.</p><p>Насонов Е.Л., Насонова В.А., Барскова В.Г. Механизмы развития подагрического воспаления. Тер арх 2006;6:77-84.</p><p>Pillinger M.H., Rosenthal P., Abeles A.M. Hyperuricemia and Gout. Bull of the NYU Hosp J Dis 2007;65:215-21.</p><p>Bouchard L., De Mеdicis R., Lussier A. et al. Inflammatory microcrystals alter the functional phenotype of human osteoblastlike cells in vitro: synergism with IL-1 to overexpress cyclooxyge-nase-2. J Immunol 2002;168:5310-7.</p><p>Lee Y.-M., Fujikado N., Manaka H. et al. IL-1 plays an important role in the bone metabolism under physiological conditions. Intern Immunol 2010;22:805-16.</p><p>CHMP post-autorisation summary of positive option for Ilaris. First published 18/01/2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines001109/smops/Positive/human_smop_00 0473.jsp&amp;mid=WC0b01ac058001d127</p><p>Schlesinger N., Alten R., Bardin T. Effect of canakinumab vs triamcinolone acetonide for treatment of gouty arthritis in patients who are unable to use nsaids and colchicine or with severe gouty arthritis. Ann Rheum Dis 2012;71(Suppl 3):439.</p><p>Zhang W., Doherty M., Bardin T. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.</p><p>Braun J., Smolen J.S. Gout: thoughts about a treat-to-target programme. Clin Exp Rheumatol 2012;30(Suppl 73):S142—S144.</p><p>Becker M.A., Schumacher H.R. Jr, Wortmann R.L. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthr Rheum 2005;52:916-23.</p><p>Shoji A., Yamanaka H., Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthr Rheum 2004;51:321-5.</p><p>Schumacher H.R. Jr, Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthr Rheum 2008;59:1540-8.</p><p>Becker M.A., Schumacher H.R., Espinoza L.R. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthr Res Ther 2011;12:R63.</p><p>Schlesinger N., Mysler E., Lin H.-Y. et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264-71.</p><p>So A., De Meulemeester M., Pikhlak A. еt al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthr Rheum 2010;62:3064-76.</p><p>Schlesinger N., De Meulemeester M., Pikhlak A. et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthr Res Ther 2011;13:R53.</p><p>Sunkureddi P., Bardin T., Alten R. et al. Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage &gt;3. Ann Rheum Dis 2012;71(Suppl 3):447.</p><p>Alten R., Bloch M., Bardin T. Efficacy and safety of canakinumab vs triamcinolone acetonide in persistent or elderly gouty arthritis patients. Ann Rheum Dis 2012;71(Suppl 3):700.</p><p>Bardin T., So A., Alten R. et al. Efficacy and safety of canakinum-ab vs triamcinolone acetonide in patients with gouty arthritis unable to use nonsteroidal anti-inflammatory drugs and colchicine, and on stable urate lowering therapy (ULT) or unable to use ULT. Arthr Rheum 2012;64(Suppl):S811—S812.</p><p>Bardin T., Schlesinger N., Alten R. et al. Surrogate markers of comorbidities: impact of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients. Ann Rheum Dis 2011;70(Suppl 3):182.</p><p>Елисеев М.С., Денисов И.С., Барскова В.Г. Оценка выживаемости больных подагрой. Тер арх 2012;5:45-50.</p><p>Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1ß inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.</p><p>Ильиных Е.В., Барскова В.Г., Александрова Е.Н. и др. С-реактивный белок при подагрическом артрите: связь с кардиоваскулярной патологией. Науч-практич ревматол 2005;6:33-7.</p><p>Kaptoge S., Di Angelantonio E., Lowe G. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.</p><p>Ridker P.M. Testing the inflammatory hypothesis of atherothrombo-sis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7(Suppl 1):332—9.</p><p>Ridker P.M., Howard C.P., Walter V. et al. Effects of interleukin-1 ß inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126(23):2739—48.</p><p>Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1ß inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.</p></div><br />